9S5 Stock Overview

Fine Foods & Pharmaceuticals N.T.M. S.p.A. More details

9S5 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	3/6
Financial Health	5/6
Dividends	1/6

Rewards

Trading at 56.3% below our estimate of its fair value

Earnings are forecast to grow 30.75% per year

Earnings grew by 672.9% over the past year

Risk Analysis

Large one-off items impacting financial results

My Notes

Capture your thoughts, links and company narrative

Fine Foods & Pharmaceuticals N.T.M. S.p.A. Competitors

Gerresheimer

XTRA:GXI

€2.4b

SCHOTT Pharma KGaA

XTRA:1SXP

€3.7b

Sartorius

XTRA:SRT3

€13.5b

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of share price highs, lows and changes for Fine Foods & Pharmaceuticals N.T.M
Historical stock prices
Current Share Price	€7.32
52 Week High	€9.20
52 Week Low	€7.32
Beta	0.67
1 Month Change	-5.67%
3 Month Change	-13.48%
1 Year Change	-11.06%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-2.40%

Recent updates

Shareholder Returns

	9S5	DE Life Sciences	DE Market
7D	-3.7%	-1.4%	-1.6%
1Y	-11.1%	-5.5%	6.8%

Return vs Industry: 9S5 underperformed the German Life Sciences industry which returned -5.6% over the past year.

Return vs Market: 9S5 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is 9S5's price volatile compared to industry and market?
9S5 volatility
9S5 Average Weekly Movement	3.2%
Life Sciences Industry Average Movement	7.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 9S5 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 9S5's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1984	780	Marco Francesco Eigenmann	www.finefoods.it

Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of drugs, food supplements, and other nutraceutical products and medical devices for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders, soluble, effervescent and chewable granules, filmed and effervescent tablets, fast melting/sublingual tablets, film-coated tablets, and hard gelatine capsules in various types of packaging, such as sachets, sticks, pillboxes, jars, blisters, tubes, and strips for various therapeutic areas, such as probiotics, multivitamins and minerals, immune systems, sleep and relax, gastrointestinal system, circulatory system, osteoarticular system, urinary system, women health, beauty, healthy ageing, and mental wellbeing. In addition, the company is involved in the production, marketing, research, and development of cosmetics products comprising liquid detergents for personal hygiene, hair care, skin care, bath and shower gels, shampoo and conditioners, shaping waxes, mouthwash and breath products, creams, gel and toothpaste, roll-on, stick and vapo spray deodrants, intimate cleansers, emulsions and microemulsions, gels, liquid soaps, skin care emulsions, oral hygiene, deodorants, and alcohol-based perfumery products in packaging, including coextruded and laminated tubes, aluminium tubes, special packs, lip sticks, air less, and various bottles and jars under its own and third-party brands.

Fine Foods & Pharmaceuticals N.T.M. S.p.A. Fundamentals Summary

How do Fine Foods & Pharmaceuticals N.T.M's earnings and revenue compare to its market cap?
9S5 fundamental statistics
Market cap	€182.15m
Earnings (TTM)	€4.85m
Revenue (TTM)	€243.35m

37.5x

P/E Ratio

0.7x

P/S Ratio

Is 9S5 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9S5 income statement (TTM)
Revenue	€243.35m
Cost of Revenue	€167.55m
Gross Profit	€75.80m
Other Expenses	€70.95m
Earnings	€4.85m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.20
Gross Margin	31.15%
Net Profit Margin	1.99%
Debt/Equity Ratio	43.2%

How did 9S5 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

113%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 06:34
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fine Foods & Pharmaceuticals N.T.M. S.p.A. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gian Gadini	Banca Akros S.p.A. (ESN)
Gianmarco Bonacina	Banca Akros S.p.A. (ESN)
Andrea Randone	Intermonte SIM S.p.A.